EUVIMEDEUVIMED entdecken
Crossref

18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival

Yizhao Xie, Yifan Chen, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shuyi Lin, Shaoli Song, Biyun Wang, Zhongyi Yang iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 374-388

DOI: 10.1007/s00259-025-07459-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 19.07.2025. Verfasst von Yizhao Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Estradiol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Science and Technology Innovation Medical Development Foundation, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether 18F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established. PATIENTS AND METHODS: We screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study. RESULTS: A total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by 18F-FES-PET before first-line treatment. 111 patients with all-FES positive metastatic lesions and 17 patients with FES heterogeneity received CDK4/6 inhibitors combined with endocrine therapy. 21 patients with all-FES negative metastatic lesions and 7 patients with FES heterogeneity received chemotherapy (CT). As for the unscreened group, 236 received CDK4/6 inhibitors combined with endocrine therapy and 81 received CT. In CDK4/6 inhibitors combined with endocrine therapy cohort, FES-screened group showed a significantly prolonged progression-free survival (PFS) compared with unscreened group (mPFS 32.4 months versus 17.3 months, Hazard Ratio = 0.49; 95% CI, 0.34 to 0.69; p < 0.0001). And chemotherapy cohort showed superior PFS for screened patients as well (mPFS 11.38 months versus 8.91 months, Hazard Ratio = 0.56; 95% CI, 0.33 to 0.94; p = 0.026). CONCLUSIONS: HR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by 18F-FES-PET/CT. This retrospective study highlights the crucial instructive role of FES assessment in evaluating ER expression in patients prior to administering first-line treatment. In the present study, improved PFS was observed when first-line therapy was guided by 18F-FES-PET in newly diagnosed HR+/HER2- MBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron Emission Tomography Computed TomographyEstradiolHumansFemaleMiddle AgedProgression-Free SurvivalRetrospective StudiesAgedErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenNeoplasm MetastasisAdult

Stichwörter der Autor:innen

18F-fluoroestradiol positron emission tomography/computed tomographyBreast cancerCDK4/6 inhibitorsER heterogeneityMetastatic breast cancer

Substanzen

EstradiolErb-b2 Receptor Tyrosine KinasesReceptors, Estrogen16-fluoroestradiolERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. shaoli-song@163.com.

ORCID-Profile: Zhongyi Yang

Förderung

  • National Natural Science Foundation of China
  • Beijing Science and Technology Innovation Medical Development Foundation
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Xie, Y., Chen, Y., Liu, C., Zhao, Y., Gong, C., Lin, S., Song, S., Wang, B., & Yang, Z. (2025). 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 374-388. https://doi.org/10.1007/s00259-025-07459-w

Vancouver

Xie Y, Chen Y, Liu C, Zhao Y, Gong C, Lin S, et al. 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):374-388. doi:10.1007/s00259-025-07459-w

BibTeX
@article{Xie2025,
  author = {Xie, Yizhao and Chen, Yifan and Liu, Cheng and Zhao, Yannan and Gong, Chengcheng and Lin, Shuyi and Song, Shaoli and Wang, Biyun and Yang, Zhongyi},
  title = {18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {374--388},
  doi = {10.1007/s00259-025-07459-w}
}
Kostenlos starten →